Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL856819 | 0.93 | SIGMAR1 (0.48) | KEAP1SMN1; SMN2ALOX15SIGMAR1CYP2D6 | |
| SCHEMBL20542527 | 0.91 | GNAI3 (0.50) | KEAP1SMN1; SMN2ALOX15SIGMAR1GNAI3 | |
| SCHEMBL101501 | 0.87 | KEAP1 (0.67) | KEAP1SMN1; SMN2ALOX15SIGMAR1CYP2D6 | |
| SCHEMBL1616800 | 0.87 | — | — | |
| SCHEMBL4395108 | 0.85 | KEAP1 (0.54) | KEAP1SMN1; SMN2ALOX15SIGMAR1CYP2D6 | |
| SCHEMBL1861653 | 0.85 | KEAP1 (0.54) | KEAP1SMN1; SMN2ALOX15SIGMAR1CYP2D6 | |
| SCHEMBL246702 | 0.84 | ALOX15 (0.72) | KEAP1SMN1; SMN2ALOX15SIGMAR1ACE2 | |
| SCHEMBL6659406 | 0.84 | KDM1A (0.48) | GNAI3GNAO1GNAI1 | |
| SCHEMBL15329386 | 0.84 | KEAP1 (0.64) | KEAP1SMN1; SMN2ALOX15SIGMAR1CYP2D6 | |
| SCHEMBL6663102 | 0.84 | GNAI3 (0.50) | GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724442-A1 | AGONISM-ANTAGONISM IN ENDOSOMAL TLRS BY MODULATING CHEMICAL FEATURES IN 8-OXOPURINE: PROCESS FOR PREPARATION AND APPLICATION THEREOF | Council of Scientific and Industrial Research (IN) | 2026-04-15 | — | — | EP | claimed |
| EP-3141552-B1 | THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | HANMI PHARM IND CO LTD (KR) | 2019-04-17 | — | — | EP | claimed |
| EP-3141552-A1 | THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | Hanmi Pharm. Co., Ltd. (KR) | 2017-03-15 | — | — | EP | claimed |
| US-20120302567-A1 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-11-29 | — | — | US | claimed |
| US-4919685-A | CONTAINING AS STORAGE STABILIZER A COPOLYMER GRAFTED WITH ALIPHATIC AND/OR ALIPHATIC POLYAMINE SUCCINIMIDE | TEXACO INC. (US) | 1990-04-24 | — | — | US | claimed |
| EP-4724442-A1 | AGONISM-ANTAGONISM IN ENDOSOMAL TLRS BY MODULATING CHEMICAL FEATURES IN 8-OXOPURINE: PROCESS FOR PREPARATION AND APPLICATION THEREOF | Council of Scientific and Industrial Research (IN) | 2026-04-15 | — | — | EP | disclosed |
| EP-4644390-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | Beyang Therapeutics Co., Ltd. (CN) | 2025-11-05 | — | — | EP | disclosed |
| CN-120078779-A | Composition for inhibiting herpesvirus | 威斯康星州医药大学股份有限公司 | 2025-06-03 | — | — | CN | disclosed |
| CN-116057046-B | Composition for inhibiting herpesvirus | 威斯康星州医药大学股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| US-12162882-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMAC, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| WO-2024129982-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20240092777-A1 | Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-03-21 | — | — | US | disclosed |
| WO-2007117180-A1 | AZAHETEROCYCLES, COMBINATORY LIBRARY, FOCUSED LIBRARY, PHARMACEUTICAL COMPOSITION AND METHODS FOR THE PRODUCTION THEREOF | 'CHEMICAL DIVERSITY RESEARCH INSTITUTE' LTD. (RU) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007092095-A2 | [4-(BENZO [B] THI0PHEN-2-YL) PYRIMIDIN-2YL] -AMINE DERIVATIVES AS IKK-BETA INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES. | ELI LILLY AND COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
| US-20070054084-A1 | Optical recording medium and compound used for the same | MITSUI CHEMICALS, INC. (JP) | 2007-03-08 | — | — | US | disclosed |
| EP-1672626-A1 | OPTICAL RECORDING MEDIUM AND COMPOUND USED IN THE OPTICAL RECORDING MEDIUM | Mitsui Chemicals, Inc. (JP) | 2006-06-21 | — | — | EP | disclosed |
| US-4992150-A | Telomer with alpha-olefin;oil and fuel additive | NIPPON OIL CO, LTD. (JP) | 1991-02-12 | — | — | US | disclosed |
| US-4267102-A | Bleomycin group antibiotics | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1981-05-12 | — | — | US | disclosed |
| US-RE30451-E | ANTITUMOR AGENTS | Zaidan Jojin Biseibutsu Kagaku Kenkyu Kai (JP) | 1980-12-16 | — | — | US | disclosed |
| US-4069064-A | Phthalocyanine formulations having high gloss, which are stabilized against recrystallization and against change of modification | BASF AKTIENGESELLSCHAFT (DT) | 1978-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302567-A1 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | CDK2, SBK3, CDK2AP1 | KEAP1 2101/4885SMN1; SMN2 3500/4885ALOX15 4356/4885 |
| US-12162882-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | FGFR1, FGFR3, FGFR2 | KEAP1 483/4885SMN1; SMN2 4245/4885ALOX15 2591/4885 |
| US-20240092777-A1 | Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors | FGFR1, FGFR3, FGFR2 | KEAP1 483/4885SMN1; SMN2 4245/4885ALOX15 2591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.